Nelfinavir

• Description :

  Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent[1][2][3].

• Product Name Alternative :

  AG1341

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  HIV; HIV Protease

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/nelfinavir.html

• Purity :

  98.65

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  [H][C@]12C[C@@H](C(NC(C)(C)C)=O)N(C[C@H]([C@@H](NC(C3=C(C)C(O)=CC=C3)=O)CSC4=CC=CC=C4)O)C[C@@]1([H])CCCC2

• Molecular Formula :

  C32H45N3O4S

• Molecular Weight :

  567.78

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Mondal D, et al. Nelfinavir suppresses signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J. 2013 Spring;13 (1) :76-90.|[2]Kaldor SW, et al. Nelfinavir mesylate (AG1343) : a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40 (24) :3979-85.|[3]Gills JJ, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that inducesendoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007 Sep 1;13 (17) :5183-94.|[4]Bono C, et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica. 2012;97 (7) :1101‐1109.|[5]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  HIV-1

• Citation 01 :

  Antimicrob Agents Chemother. 2020 Aug 20;64 (9) :e00872-20.|Antiviral Res. 2022 Jun;202:105311.|bioRxiv. 2020 May.|bioRxiv. 2024 November 03.|Int J Antimicrob Agents. 2019 Dec;54 (6) :814-819.|J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|PLoS One. 2015 Aug 11;10 (8) :e0134707. |bioRxiv. 2021 Feb 1.|Cell Signal. 2020 Nov;75:109775.|Cells. 2022 Nov 12;11 (22) :3580.|Nat Commun. 2020 Sep 4;11 (1) :4417.|Patent. US20250123269A1.|Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|Viruses. 2022 Jun 23;14 (7) :1369.

• CAS Number :

  [159989-64-7]